Genodermatoses

Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021

A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.

Key Points: 
  • A live webcast of the Wedbush PacGrow panel discussion will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section.
  • A replay of the webcast will be available approximately one hour following the live event.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
  • Zokinvyfor the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

Retrieved on: 
Tuesday, August 3, 2021

Hormonal therapies targeting ER, such as SERDs, can be effective in treating ER+ mBC, but over 90% of patients eventually develop resistance to ER-targeted therapy.

Key Points: 
  • Hormonal therapies targeting ER, such as SERDs, can be effective in treating ER+ mBC, but over 90% of patients eventually develop resistance to ER-targeted therapy.
  • We are committed to exploring the full potential of mirdametinib on behalf of patients with devastating cancers and look forward to collaborating with Dr. Rosen and his colleagues at MSK on this important trial.
  • In addition, mirdametinib is being evaluated in a Phase 1b/2 trial in combination with BeiGenes RAF dimer inhibitor, lifirafenib, in patients with advanced or refractory solid tumors harboring RAS mutations, RAF mutations, and other MAPK pathway aberrations.
  • NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, July 28, 2021

REDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021.

Key Points: 
  • REDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021.
  • The Soleno team remains focused on achieving regulatory approval for DCCR for the treatment of Prader-Willi syndrome, or PWS, saidAnish Bhatnagar, M.D., Chief Executive Officer ofSoleno Therapeutics.
  • OnJuly 2, 2021, the Company received official meeting minutes from theJune 11, 2021, Type B meeting with theDivision of Diabetes, Lipid Disorders and Obesity.
  • Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Netherton Syndrome Epidemiology Research Report 2021-2030: Focus on United States, Japan, Germany, France, Italy, Spain, United Kingdom - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021

This 'Netherton Syndrome - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This 'Netherton Syndrome - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical and forecasted Netherton Syndrome epidemiology segmented as Prevalent Population of Netherton Syndrome and Severity-specific cases of Netherton Syndrome.
  • The epidemiology segment also provides the Netherton Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report provides the segmentation of the Netherton Syndrome epidemiology by Severity-specific cases of Netherton Syndrome in the 7MM.

Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa

Retrieved on: 
Friday, July 23, 2021

The EB-101 pivotal VIITAL study is currently ongoing at Stanford University Medical Center in Palo Alto, CA.

Key Points: 
  • The EB-101 pivotal VIITAL study is currently ongoing at Stanford University Medical Center in Palo Alto, CA.
  • EB-101 is an autologous, gene-corrected cell therapy currently being investigated in Abeonas pivotal Phase 3 VIITAL study for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy.
  • The EB-101 VIITAL study is a randomized clinical trial enrolling 10 to 15 RDEB patients with approximately 35 large, chronic wound sites treated in total.
  • Abeona produces EB-101 for the VIITAL study at its fully integrated gene and cell therapy manufacturing facility in Cleveland, OH.

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

Retrieved on: 
Thursday, July 22, 2021

PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call onThursday, August 5, 2021at4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.

Key Points: 
  • PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call onThursday, August 5, 2021at4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
  • Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.
  • Zokinvyfor the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

Retrieved on: 
Thursday, July 22, 2021

Based on the feedback received, Radius plans on initiating a pivotal Phase 2/3 global study for patients with PWS.

Key Points: 
  • Based on the feedback received, Radius plans on initiating a pivotal Phase 2/3 global study for patients with PWS.
  • Radius plans to initiate the pivotal Phase 2/3 study, to be branded as SCOUT (Synthetic Cannabidiol Oral Solution), by end of this year or early first quarter of 2022.
  • With this current initiation timeline, it is anticipated top line results would be available in the second half of 2024.
  • Radius is initially targeting Prader-Willi syndrome (PWS) and anticipates initiating a seamless pivotal Phase 2/3 study for patients with PWS in the second half of 2021.

Global Epidermolysis Bullosa Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Epidermolysis Bullosa Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Epidermolysis Bullosa Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Epidermolysis Bullosa Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Epidermolysis Bullosa market.
  • It covers emerging therapies for Epidermolysis Bullosa in active clinical development stages including early and late stage clinical trials.
  • The report provides Epidermolysis Bullosa pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting

Retrieved on: 
Wednesday, July 7, 2021

The results were reported in a poster, titled Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa Following EB-101 Treatment of Large, Chronic Wounds, at the Society for Pediatric Dermatology (SPD) 46th Annual Meeting.

Key Points: 
  • The results were reported in a poster, titled Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa Following EB-101 Treatment of Large, Chronic Wounds, at the Society for Pediatric Dermatology (SPD) 46th Annual Meeting.
  • The updated results also included investigator assessment of the presence of pain in treated wounds up to six years following treatment with EB-101.
  • Abeona produces EB-101 for the VIITAL study at its fully integrated gene and cell therapy manufacturing facility in Cleveland, OH.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.

How to Treat Keratosis Pilaris at Home; American Academy of Dermatology

Retrieved on: 
Thursday, June 24, 2021

Keratosis pilaris causes tiny, rough feeling bumps to appear on the skin, most often on the upper arms and thighs.

Key Points: 
  • Keratosis pilaris causes tiny, rough feeling bumps to appear on the skin, most often on the upper arms and thighs.
  • While treatment isnt necessary for keratosis pilaris, if the itch, dryness or appearance is bothersome, there are things you can do at home to help.
  • Spending too much time in the water can dry your skin and cause keratosis pilaris to flare.
  • These tips are demonstrated in How to Treat Keratosis Pilaris at Home , a video posted to the AAD website and YouTube channel .